GlassScriptPhysician profile
Ashley Ingolia
NPI 1578959631
$780.06
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $65.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.04 | 2019 | |
| Novo Nordisk INC | $95.02 | 2019 | |
| Amgen INC. | $88.30 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.90 | 2019 | |
| Pfizer INC. | $52.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.21 | 2019 | |
| Amarin Pharma, INC. | $44.29 | 2019 | |
| Daiichi Sankyo INC. | $28.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.00 | 2019 | |
| Ge Healthcare | $19.91 | 2019 | |
| Smith+Nephew, INC. | $18.48 | 2019 | |
| Shire North American Group INC | $17.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2019 | |
| Astellas Pharma US INC | $17.05 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2019 | |
| Lilly USA, LLC | $15.56 | 2019 | |
| Genentech USA, INC. | $15.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ingolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.